Dompé U.S. Settles False Claims Act Allegations for $32 Million Over Eyedrop Marketing
Dompé U.S. Inc. has agreed to pay $32 million to resolve False Claims Act liability stemming from allegations that the pharmaceutical company improperly induced prescriptions for its specialty ophthalmic product, Oxervate. According to the U.S. Department of Justice, the settlement addresses claims that Dompé provided unlawful remuneration to specialty pharmacies to influence healthcare providers and patients.
Unraveling the Mechanics of the Oxervate Marketing Scheme
At the center of the federal investigation was Oxervate (cenegermin), a high-cost biological product approved for the treatment of neurotrophic keratitis, a rare corneal disease. Federal prosecutors alleged that Dompé utilized intricate financial arrangements with specialty pharmacies, effectively sidestepping federal safeguards designed to keep commercial kickbacks out of medical decision-making. The Department of Justice maintained that these inducements violated the Anti-Kickback Statute, which prohibits offering or paying remuneration to induce the purchase of items covered by federal healthcare programs like Medicare.
By allegedly leveraging these financial ties, the company sought to secure a captive distribution channel and drive prescription volume for a medication carrying a substantial price tag. Federal enforcement actions of this scale underscore the ongoing scrutiny facing specialty drug manufacturers operating within tightly regulated therapeutic niches. Legal analysts frequently note that high-cost biologics and orphan drugs attract intense oversight due to the financial pressures they place on federal healthcare programs.
The Regulatory Framework and Enforcement Priorities
The resolution highlights the federal government’s aggressive posture toward pharmaceutical marketing practices that threaten the integrity of public healthcare expenditures. The Anti-Kickback Statute remains a cornerstone of healthcare enforcement, designed to ensure that clinical choices are driven by patient needs rather than commercial incentives. Whistleblower provisions under the False Claims Act also played a pivotal role in bringing these allegations to light, rewarding private parties who expose fraud against the government.
According to a statement released by the U.S. Department of Justice regarding enforcement actions under the False Claims Act, civil settlements of this magnitude serve as a sharp deterrent for manufacturers tempted to blur the lines between legitimate patient support and improper financial influence. As federal agencies coordinate more closely with state regulators, pharmaceutical compliance programs face unprecedented demands for operational transparency.
Broader Industry Ripples and Compliance Takeaways
This multi-million-dollar accord sends a clear operational signal to emerging biotech firms and established pharmaceutical giants alike. Compliance structures surrounding hub services, copay assistance, and specialty pharmacy networks are undergoing rigorous internal audits across the sector. Companies marketing high-value therapeutics must now navigate an environment where federal authorities scrutinize every contractual relationship tied to product distribution.
As the pharmaceutical industry absorbs the financial and reputational fallout of the settlement, executive leadership faces mounting pressure to fortify internal oversight. Ensuring that commercial strategies strictly adhere to healthcare regulations is no longer merely a legal formality, but an existential prerequisite for market longevity. What steps should pharmaceutical companies take next to overhaul their specialty pharmacy oversight?
